AbbVie explores flow chemistry platforms and MS-based analytical technologies to accelerate drug discovery

SMi has confirmed that announce that Stevan W Djuric, Distinguished Research Fellow and Senior Director at AbbVie will be presenting a keynote at Drug Discovery 2017, with a focus on novel technologies to accessing new chemical matter.

Stevan's exclusive presentation will explore the application of enabling chemistry technology to the acceleration of the drug discovery process. He will elaborate on flow chemistry platforms including compound library synthesis using segmented flow, photochemistry, electrochemistry, and access to novel heterocycles through high temperature chemistry. He will also demonstrate how MS-based analytical technologies can be applied to drug distribution and product protection.

In the lead up to the event, Stevan has commented about AbbVie’s work in drug discovery. “We have made significant investments in several enabling chemistry technologies including flow chemistry, integrated synthesis and bioassay platforms and MS based initiatives. Many of these have helped reduce cycle time, and increase success rates.

"From a chemistry perspective – flow chemistry, particularly in the process chemistry area, new synthetic methodologies such as C-H activation chemistry have allowed easier access to a greater variety of target molecules and DNA encoded libraries are beginning to show promise as a mainstream HTS screening technology."

Stevan will be speaking on Day 2 of the conference and joins lead decision-makers and industry innovators from AstraZeneca, Sanofi, Takeda, Merck Serono, AbbVie, GSK, Johnson & Johnson, UCB Pharma, Eli Lilly and more. A full list of speakers can be found on www.drug-discovery.co.uk/openpr.

SMi’s Drug Discovery conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.

The event will also feature two post-conference workshops on new approaches in lead generation and applications of physicochemical and biomimetic properties in early drug discovery.

For more details about the conference and registration information, visit www.drug-discovery.co.uk/openpr.

DRUG DISCOVERY
27 – 28 MARCH 2017
Holiday Inn Kensington Forum
www.drug-discovery.co.uk/openpr

---end ---

Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Fateja Begum at fbegum@smi-online.co.uk. For media queries please contact Honey de Gracia at hdegracia@smi-online.co.uk.

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

1 Westminster Bridge Road, London, SE1 7XW

This release was published on openPR.